Compare TELA & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TELA | GRML |
|---|---|---|
| Founded | 2012 | N/A |
| Country | United States | United States |
| Employees | N/A | 5 |
| Industry | Medical/Dental Instruments | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.3M | 34.9M |
| IPO Year | 2019 | 2022 |
| Metric | TELA | GRML |
|---|---|---|
| Price | $0.70 | $0.19 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $2.00 | N/A |
| AVG Volume (30 Days) | 51.2K | ★ 7.6M |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.59 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $80,275,000.00 | N/A |
| Revenue This Year | $10.23 | N/A |
| Revenue Next Year | $14.26 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.84 | N/A |
| 52 Week Low | $0.50 | $0.16 |
| 52 Week High | $2.14 | $0.55 |
| Indicator | TELA | GRML |
|---|---|---|
| Relative Strength Index (RSI) | 41.34 | 41.63 |
| Support Level | $0.67 | $0.16 |
| Resistance Level | $0.75 | $0.34 |
| Average True Range (ATR) | 0.09 | 0.04 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 1.02 | 27.86 |
TELA Bio Inc a commercial-stage medical technology company focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.